Trademark: 79342589
Word
ASTARTZ
Status Date
Tuesday, August 22, 2023
Registration Number
7141339
Registration Date
Tuesday, August 22, 2023
Filing Date
Friday, February 25, 2022
Published for Opposition
Tuesday, June 6, 2023
40 Custom manufacture of pharmaceuticals; custom manufacture of investigational new drug; custom manufacture of radiopharmaceuticals; custom synthesis of labeled compound; custom manufacture of peptides; custom manufacture of antibodies; custom manufacture of proteins; custom protein modification; custom antibody modification; custom extraction of pharmaceuticals and veterinary preparations; custom synthesis and refining of pharmaceuticals and veterinary preparations; custom peptide synthesis services; custom synthesis and refining of pharmaceuticals consisting of antibodies; custom manufacture of pharmaceuticals consisting of antibodies; custom synthesis and refining of pharmaceuticals consisting of antibody fragments; custom manufacture of pharmaceuticals consisting of antibody fragments; custom synthesis and refining of pharmaceuticals consisting of antibody derivatives; custom manufacture of pharmaceuticals consisting of antibody derivatives; custom radioactive labeling of antibodies; custom radioactive labeling of antibody fragments; custom radioactive labeling of antibody derivatives; custom radioactive labeling of peptides
5 Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the diagnosis of cancer; chemical reagents for medical purposes; medical diagnostic reagents; radioactive substances for medical purposes; isotopes for medical purposes; radioisotope markers for therapeutic or diagnostic use; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; synthetic peptides for pharmaceutical purposes for the treatment of cancer; synthetic peptides for pharmaceutical purposes for the diagnosis of cancer; pharmaceuticals consisting of antibodies for the treatment of cancer; pharmaceuticals consisting of antibodies for the diagnosis of cancer; pharmaceuticals consisting of antibody fragments for the treatment of cancer; pharmaceuticals consisting of antibody fragments for the diagnosis of cancer; pharmaceuticals consisting of antibody derivatives for the treatment of cancer; pharmaceuticals consisting of antibody derivatives for the diagnosis of cancer; antibodies for medical purposes
1 Industrial chemicals; chemical preparations for scientific purposes; diagnostic reagents for scientific or research use; chemicals for use in the manufacture of pharmaceuticals; chemicals for use in the manufacture of radiopharmaceuticals; radioactive elements for scientific purposes; isotopes for industrial purposes; peptide substrates for scientific purposes; peptide for use in the manufacture of pharmaceuticals; chelating agents for use in the manufacture of pharmaceuticals; polypeptides for scientific purposes; antibodies for scientific purposes, other than for medical or veterinary use; chelate compound; organic chelating agents; metal chelating agents
45 Granting of licenses to others for the use of intellectual property; legal services, namely, exploitation of industrial property rights
42 Research and development of medicines; testing, inspection or research services in the fields of pharmaceuticals; advisory, consultancy and providing information relating to testing, inspection or research services in the fields of pharmaceuticals; development of pharmaceuticals; advisory, consultancy and providing information relating to development of pharmaceuticals; conducting clinical trials for pharmaceuticals for others; advisory, consultancy and providing information relating to clinical trials for pharmaceuticals; research and development of radiopharmaceuticals; development of radiopharmaceuticals; advisory, consultancy and providing information relating to development of radiopharmaceuticals; research and development services relating to peptides; research and development services in the field of antibodies; research and development services relating to peptide labeling by radioactive substances; research and development services relating to antibody labeling by radioactive substances
The mark consists of the Greek letter "alpha" before the term "STARTZ" appearing as one word in stylized format.
In the statement, line 56 and 57, " The mark consists of the Greek letter alpha plus the term "STARTZ" appearing as "aSTARTZ" and pronounced as "alphaSTARTZ," in stylized format." should be deleted, and "The mark consists of the Greek letter "alpha" before the term "STARTZ" appearing as one word in stylized format." should be inserted.
Jun 16, 2022
Sn Assigned For Sect 66a Appl From Ib
Jun 22, 2022
Limitation From Original Application Entered
Jun 23, 2022
New Application Office Supplied Data Entered
Jun 28, 2022
Application Filing Receipt Mailed
Sep 30, 2022
New Representative At Ib Received
Dec 9, 2022
Assigned To Examiner
Dec 19, 2022
Non-Final Action Written
Dec 20, 2022
Non-Final Action (Ib Refusal) Prepared For Review
Feb 15, 2023
Refusal Processed By Mpu
Feb 15, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Mar 6, 2023
Refusal Processed By Ib
Apr 17, 2023
Teas Response To Office Action Received
Apr 17, 2023
Correspondence Received In Law Office
Apr 18, 2023
Teas/Email Correspondence Entered
Apr 19, 2023
Approved For Pub - Principal Register
Apr 22, 2023
Teas Post Publication Amendment Received
Apr 25, 2023
Withdrawn From Pub - Managing Attorney Request
Apr 26, 2023
Previous Allowance Count Withdrawn
May 1, 2023
Examiners Amendment -Written
May 1, 2023
Examiners Amendment E-Mailed
May 1, 2023
Notification Of Examiners Amendment E-Mailed
May 1, 2023
Examiner's Amendment Entered
May 1, 2023
Approved For Pub - Principal Register
May 15, 2023
Assigned To Petition Staff
May 17, 2023
Notification Of Notice Of Publication E-Mailed
May 17, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
May 17, 2023
Notification Of Possible Opposition Sent To Ib
Jun 6, 2023
Published For Opposition
Jun 6, 2023
Official Gazette Publication Confirmation E-Mailed
Jun 6, 2023
Changes/Corrections After Pub Approval Entered
Jun 6, 2023
Notification Processed By Ib
Aug 22, 2023
Registered-Principal Register
Aug 22, 2023
Notice Of Registration Confirmation Emailed
Aug 28, 2023
Teas Section 7 Request Received
Nov 22, 2023
Final Disposition Notice Created, To Be Sent To Ib
Nov 27, 2023
Final Disposition Processed
Nov 27, 2023
Final Disposition Notice Sent To Ib
Dec 19, 2023
Final Decision Transaction Processed By Ib
May 9, 2024
Case Assigned To Post Registration Paralegal
May 10, 2024
Correction Under Section 7 - Processed
Jun 18, 2024
Notice Of Updated Registration Confirmation Emailed
Trademark Alertz updated from USPTO on 2030-01-24
